Overview

Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension

Status:
Terminated

Trial end date:
2013-11-01

Target enrollment:

Participant gender:

Summary

This is an open-label non-randomized, pilot study to evaluate the effect of Interleukin-1 blockade on exercise capacity in patients with pulmonary hypertension. Subjects will undergo cardiopulmonary exercise testing at baseline, and after 4 weeks treatment with Anakinra (recombinant human Interleukin-1 receptor antagonist.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Virginia Commonwealth University

Treatments:

Interleukin 1 Receptor Antagonist Protein